Search Results
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Dr. George Chen, Founder, Chairman, and Chief Executive Officer of D3 Bio. "We believe these results support the continued and accelerated evaluation of elisrasib in Phase 3 randomized studies."About Elisrasib (D3S-001)Elisrasib is a next-generation KRAS G12C inhibitor designed for
More news about: D3 Bio
May 31, 2026, 20:00 ET 마이크로아이피, 컴퓨텍스 2026에서 'AI 차량 시스템 비즈니스 그룹' 및 엣지 AI 혁신 기술 첫선
줄인다.ASIC 설계 및 생태계 파트너십칩 설계 부문에서 마이크로아이피의 'CATS 맞춤형 ASIC 기술 및 솔루션(CATS Customized ASIC Technology and Solutions)'은 첨단 AI EDA 도구를 통합해 R&D 팀이 칩 출시 기간을 6~9개월 단축할 수 있도록 지원한다. 행사에서 마이크로아이피는 '무료 ASIC 설계 기술 컨설팅 서비스(Free ASIC Design Technical Consulting Service)'를 제공하며, 통합 가능성을 평가하기 위한 독점 PPA
More news about: MICROIP
May 31, 2026, 20:00 ET Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders
late 2025, we partnered with CyberPowerPC to offer the Ice Pad as a pre-applied upgrade, and this week, AMD announced it as part of its Ryzen™ 7 5800X3D bundle. Now, with Noctua, we're bringing the power of the Carbice® IP90 thermal pads to all DIY builders who want to maintain performance and
More news about: Carbice Corporation
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
clinical study of IBI363 for IO-resistant non-squamous NSCLC is also planned. Innovent and Takeda are co-developing IBI363 (Takeda R&D code: TAK-928) globally.SAN FRANCISCO and SUZHOU, China, May 31,
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 德昇濟醫藥在ASCO 2026公布Elisrasib（D3S-001）一線治療數據；新一代KRAS G12C抑制劑在初治NSCLC中展現裡程碑式療效
KRAS G12C突變NSCLC在聯合治療隊列中，共有52例既往未接受治療的G12C突變NSCLC患者接受elisrasib 600 mg每日一次聯合帕博利珠單抗200 mg每3周一次（Q3W）治療，中位隨訪時間為5.7個月。值得注意的是，聯合方案中elisrasib的給藥劑量即為其RP2D（600 mg QD），可實現對KRAS G12C靶點的完全覆蓋。elisrasib聯合帕博利珠單抗在既往未接受治療的G12C突變NSCLC患者中展現出極具說服力的抗腫瘤活性。在48例療效可評估患者中，ORR為81.3%，且在各PD-L1表達水平人群中均觀察到療效：PD-L1
More news about: 德昇濟醫藥（D3 Bio）
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
chemotherapy in the first-line treatment of advanced NSCLC (all PD-L1 expression levels)Innovent and Takeda are co-developing IBI363 (Takeda R&D code: TAK-928) globally.SAN FRANCISCO and SUZHOU, China, May 31,
More news about: Innovent Biologics
May 31, 2026, 20:00 ET MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026
PartnershipsFor chip design, MICROIP's "CATS Customized ASIC Technology and Solutions" integrates advanced AI EDA tools to assist R&D teams in shortening chip time-to-market by 6 to 9 months. At the event, MICROIP will offer a "Free ASIC Design Technical Consulting Service,"
More news about: MICROIP
May 31, 2026, 20:00 ET MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026
Ecosystem PartnershipsFor chip design, MICROIP's "CATS Customized ASIC Technology and Solutions" integrates advanced AI EDA tools to assist R&D teams in shortening chip time-to-market by 6 to 9 months. At the event, MICROIP will offer a "Free ASIC Design Technical Consulting Service," providing
More news about: MICROIP
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
a long-term vision, free of influence from fiduciary responsibilities. Servier invests close to 20% of revenue from brand-name medicines in R&D each year. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its
More news about: Servier Pharmaceuticals
May 31, 2026, 16:32 ET Creality Rayakan 12 Tahun Inovasi dengan KliTek™ dan Ekspansi Ekosistem Berbasis AI
industri printer 3D konsumen di pasar global, terus mengembangkan teknologi pencetakan 3D yang mudah diakses. Dengan teknologi ini, pengguna di seluruh dunia dapat mengubah ide menjadi karya nyata. Berawal dari produsen printer 3D desktop, Creality kini berkembang sebagai ekosistem kreasi 3D konsumen berskala
More news about: Creality
May 31, 2026, 16:30 ET Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
documents can be obtained free of charge from the sources indicated above. Contacts:Berkshire HathawayMarc D. HamburgCharles C. Chang(402) 346-1400Taylor MorrisonInvestors:Mackenzie Aron(407) 906-6262
More news about: Taylor Morrison Home Corporation
May 31, 2026, 12:03 ET iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
develop children's abilities in speaking, critical thinking, independent reading and creativity. Leveraging advanced technological capabilities, including 3D engines, AI/AR functionality, and big data analysis on children's behavior & psychology, iHuman believes it will continue to provide superior experience
More news about: iHuman Inc.
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform,
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
Dunn LA, Ho AL, Pfister DG. Head and neck cancer: a review. JAMA. 2026;335(6):531-541. doi:10.1001/jama.2025.217336 Soulieres D, et al. LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head
More news about: Johnson & Johnson
May 31, 2026, 08:00 ET GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
https://cancerdetection.norc.org/ (2022).[3] Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol.
More news about: GRAIL, Inc.
May 31, 2026, 05:30 ET MARSTEK Unveils the New VENUS Family, Expanding Plug-in Batteries into a New Era of Home Energy Storage
MARSTEK as it continues accelerating the evolution of plug-in energy storage solutions for European households. Guests toured MARSTEK's Battery R&D Institute, R&D Center, Testing Laboratory, Experimental Center and production lines, including the VENUS E Gen 3.0 production line, inverter manufacturing
More news about: Marstek Energy Co., Limited
May 31, 2026, 05:30 ET MARSTEK presenta la familia VENUS, impulsando una nueva era de baterías plug-in residenciales
evolución de las soluciones de almacenamiento energético plug-in para hogares europeos. Los invitados visitaron el Instituto de I+D de baterías de MARSTEK, el Centro de I+D, el laboratorio de pruebas, el centro experimental y las líneas de producción, incluida la línea de producción VENUS E Gen 3.0, la
More news about: Marstek Energy Co., Limited
May 31, 2026, 05:30 ET MARSTEK dévoile la nouvelle gamme VENUS et fait entrer les batteries plug-in dans une nouvelle ère du stockage d'énergie résidentiel
l'entreprise continue d'accélérer l'évolution des solutions de stockage d'énergie plug‑in pour les foyers européens. Les invités ont visité le laboratoire de R&D sur les batteries, le laboratoire d'essais de fiabilité ainsi que les lignes de production automatisées de MARSTEK, dont la chaîne de production du
More news about: Marstek Energy Co., Limited
May 31, 2026, 05:02 ET Zoomlion acelera a implantação global de máquinas agrícolas com inovações em produtos híbridos e inteligentes
https://mma.prnewswire.com/media/2990523/231acf39e33f13402c81004afd388d54.jpg
More news about: Zoomlion
May 31, 2026, 04:54 ET Zoomlion acelera la distribución de maquinarias agrícolas a nivel mundial con avances en productos híbridos e inteligentes
https://mma.prnewswire.com/media/2990525/231acf39e33f13402c81004afd388d54.jpg
More news about: Zoomlion
May 31, 2026, 04:36 ET Zoomlion accélère le déploiement de machines agricoles au niveau mondial grâce à des produits hybrides et intelligents
https://mma.prnewswire.com/media/2990497/231acf39e33f13402c81004afd388d54.jpg
More news about: Zoomlion
May 31, 2026, 04:31 ET Zoomlion treibt den weltweiten Einsatz von Landmaschinen durch Fortschritte bei Hybrid- und intelligenten Produkten voran
https://mma.prnewswire.com/media/2990497/231acf39e33f13402c81004afd388d54.jpg
More news about: Zoomlion
May 30, 2026, 22:02 ET Cook County Treasurer Maria Pappas' Historic Property Tax Sale Reform Legislation Passes in Illinois General Assembly
Toni Preckwinkle, downstate county treasurers and housing advocates, and in collaboration with state Sen. Celina Villanueva (D-Chicago) and state Rep. Curtis Tarver (D-Chicago)."This bill is going to help a lot of people," Pappas said. "For too long, families who fell behind on their taxes risked
More news about: Cook County Treasurer Maria Pappas
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
by MSD.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
May 30, 2026, 17:23 ET XCMG, 제8회 국제 고객 페스티벌에서 미화 10억 달러 이상 주문 확보하며 글로벌 파트너십 확대
multimedia:https://www.prnewswire.com/kr/news-releases/u0078u0063u006Du0067u002Cu002DuC81Cu0038uD68Cu002DuAD6DuC81Cu002DuACE0uAC1Du002DuD398uC2A4uD2F0uBC8CuC5D0uC11Cu002DuBBF8uD654u002Du0031u0030-302786348.htmlSOURCE
More news about: XCMG Machinery